We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Dr. Esteller Discusses: Open Access

Twitter Interview – #DrEstellerChatsOA – @tandfbiosci
23 September – 9am BST | 8am UTC | 10am CEST

Introducing Dr. Manel Esteller, Editor-in-Chief, Epigenetics

Dr. Manel Esteller graduated in Medicine from the University of Barcelona, where he also obtained his Ph.D. degree specialising in cancer molecular genetics. He is the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor, as well as the Editor-in-Chief of Epigenetics.

His current research is devoted to the establishment of the epigenome and epitranscriptome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.

Author of more than 600 original publications in peer-reviewed scientific journals, 24 of them categorized as “Highly Cited Paper”, Dr. Esteller is considered among the Top 0.01% of World Scientists based on Impact by both the Stanford University (METRICS) and the Web of Science Group-Clarivate Analytics. In 2021 he was been elected as Member of the Academia Europaea and of the European Academy of Sciences.

Join us for a Twitter interview: #DrEstellerChatsOA

From 2023, Epigenetics is converting to a fully open access journal (having operated under a hybrid model previously). We will be chatting to Dr. Esteller via Twitter (@Tandfbiosci) on 23 September at 9am (BST) to discuss this move, the journal, and why open access research is so important to the field. Follow along or join in the discussion using the hashtag: #DrEstellerChatsOA

Join the conversation:
#DrEstellerChatsOA
23 September
9am BST | 8am UTC | 10am CEST

Epigenetics is particularly interested in receiving manuscripts on:

  • DNA methylation

  • Nucleosome positing and modification

  • Gene silencing

  • Imprinting

  • Chromatin remodeling

  • Non-coding RNA

  • Dosage compensation

  • Epigenetic therapy and diagnostics

  • Cancer epigenetics

  • Neuroepigenetics

Why publish open access?

  • Increase the visibility and readership of your research by publishing in a fully open access journal.

  • Make an impact beyond the academy by making your article accessible to anyone, anywhere (including readers in industry and even policy-makers).

  • Benefit from format-free submission, saving you more time for your research.

  • Freely share your work with no restrictions or paywall.

  • Retain ownership of your research through our unrestrictive publishing agreements.

  • Discounts and waivers for researchers in developing countries are available. The journal will also consider requests for discretionary APC waivers. Find out if your institution or country has an open access agreement to publish with us.

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.